Takuji Okusaka
#145,598
Most Influential Person Now
Researcher
Takuji Okusaka's AcademicInfluence.com Rankings
Takuji Okusakacomputer-science Degrees
Computer Science
#7275
World Rank
#7662
Historical Rank
Computational Linguistics
#1425
World Rank
#1441
Historical Rank
Machine Learning
#2636
World Rank
#2671
Historical Rank
Artificial Intelligence
#2930
World Rank
#2975
Historical Rank
Download Badge
Computer Science
Takuji Okusaka's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science University of Tokyo
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Takuji Okusaka Influential?
(Suggest an Edit or Addition)Takuji Okusaka's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Everolimus for advanced pancreatic neuroendocrine tumors. (2011) (1062)
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (969)
- Genomic spectra of biliary tract cancer (2015) (809)
- Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators (2012) (777)
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. (2015) (639)
- Trans-ancestry mutational landscape of hepatocellular carcinoma genomes (2014) (600)
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan (2010) (578)
- Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin (2004) (556)
- Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer (2016) (528)
- Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. (2013) (521)
- JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan (2014) (515)
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. (2011) (485)
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020) (461)
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma (2014) (380)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. (2011) (362)
- Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. (2014) (304)
- Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial (2019) (298)
- Japan Pancreatic Cancer Registry; 30th Year Anniversary: Japan Pancreas Society (2012) (280)
- High-resolution characterization of a hepatocellular carcinoma genome (2011) (274)
- Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis (2014) (271)
- A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation (2007) (260)
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma (2016) (255)
- Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features (2002) (204)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update (2014) (189)
- Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system (2014) (182)
- Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. (2006) (180)
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. (2019) (180)
- Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection (1996) (180)
- Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition (2015) (170)
- Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. (2018) (170)
- A late phase II study of S-1 for metastatic pancreatic cancer (2008) (168)
- Chemotherapy for hepatocellular carcinoma: current status and future perspectives (2018) (162)
- Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer (2015) (157)
- Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society: A Synopsis (2017) (151)
- Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer (2006) (148)
- Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. (2001) (147)
- Phase II study of S-1 in patients with advanced biliary tract cancer (2004) (144)
- Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. (2010) (140)
- S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study (2008) (139)
- Genome-Wide Association Study of Pancreatic Cancer in Japanese Population (2010) (137)
- Elevated serum interleukin-6 levels in patients with pancreatic cancer. (1998) (136)
- Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study (2017) (136)
- Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer (2014) (134)
- Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. (2016) (129)
- Possible detection of pancreatic cancer by plasma protein profiling. (2005) (128)
- A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). (2018) (123)
- A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. (2015) (122)
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study (2021) (122)
- Radiofrequency ablation and percutaneous ethanol injection in patients with small hepatocellular carcinoma: a comparative study. (2001) (121)
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma (2015) (120)
- Association of Pancreatic Fatty Infiltration With Pancreatic Ductal Adenocarcinoma (2014) (118)
- An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic Cancer (2005) (117)
- Needle tract implantation of hepatocellular carcinoma after percutaneous ethanol injection (1998) (113)
- Prognosis of hepatocellular carcinoma patients with extrahepatic metastases. (1997) (105)
- Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) Randomized Phase III Clinical Trial. (2019) (105)
- Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial (2016) (102)
- Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer (2004) (100)
- REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset (2019) (99)
- Prognostic Factors in Patients with Metastatic Pancreatic Adenocarcinoma Receiving Systemic Chemotherapy (2000) (95)
- A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma (2011) (95)
- Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin (2005) (93)
- Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805) (2013) (90)
- Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. (2009) (86)
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (2022) (86)
- A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. (2007) (85)
- Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. (2016) (82)
- Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. (2016) (81)
- Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab (2017) (81)
- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). (2020) (81)
- A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer (2018) (80)
- Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy (2001) (80)
- Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma (2013) (79)
- Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score (2017) (78)
- Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer (2011) (78)
- A phase II trial of continuous infusion of 5‐fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma (2005) (77)
- Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response Analyses (2017) (73)
- Analysis of Prognostic Factors Affecting Survival After Initial Recurrence and Treatment Efficacy for Recurrence in Patients Undergoing Potentially Curative Hepatectomy for Hepatocellular Carcinoma (2007) (72)
- Phase I trial of gemcitabine in patients with advanced pancreatic cancer. (2001) (72)
- Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study (2014) (72)
- Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics (2016) (71)
- Phase II Trial of Intra-Arterial Chemotherapy using a Novel Lipophilic Platinum Derivative (SM-11355) in Patients with Hepatocellular Carcinoma (2004) (71)
- Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. (2013) (71)
- A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer (2008) (69)
- Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study (2015) (68)
- Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer (2017) (65)
- Identification of Adipophilin as a Potential Plasma Biomarker for Colorectal Cancer Using Label-Free Quantitative Mass Spectrometry and Protein Microarray (2011) (65)
- Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma (2013) (65)
- Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. (2010) (65)
- Protracted 5‐fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma (1997) (65)
- Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma (2014) (64)
- A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). (2018) (63)
- Phase 1 and pharmacological trial of OPB‐31121, a signal transducer and activator of transcription‐3 inhibitor, in patients with advanced hepatocellular carcinoma (2015) (63)
- A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results (2019) (61)
- A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer (2002) (61)
- Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. (2015) (60)
- Germline mutations in Japanese familial pancreatic cancer patients (2016) (60)
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. (2017) (60)
- Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial (2017) (60)
- Dose‐response Trial of Lactoferrin in Patients with Chronic Hepatitis C (2002) (58)
- Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms (2015) (57)
- Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients (2009) (55)
- Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray (2011) (55)
- Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition (2020) (54)
- Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. (2007) (53)
- A Phase I Study of Combination Chemotherapy with Gemcitabine and Oral S-1 for Advanced Pancreatic Cancer (2005) (53)
- A National Survey to Systematically Identify Factors Associated With Oncologists' Attitudes Toward End-of-Life Discussions: What Determines Timing of End-of-Life Discussions? (2015) (53)
- Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer (2011) (52)
- A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. (2013) (52)
- Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. (2009) (51)
- New developments in systemic therapy for advanced biliary tract cancer (2018) (51)
- Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients (2010) (50)
- A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117. (2020) (50)
- Comparison of Chemotherapeutic Treatment Outcomes of Advanced Extrapulmonary Neuroendocrine Carcinomas and Advanced Small-Cell Lung Carcinoma (2012) (50)
- A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer (2007) (50)
- A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer (2013) (49)
- A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). (2020) (49)
- S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. (2017) (49)
- Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. (1997) (49)
- Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. (2019) (48)
- A phase II study of cisplatin in patients with biliary tract carcinoma. (1994) (48)
- Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial (2012) (48)
- Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. (2018) (48)
- Prognostic Factors in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy (1996) (48)
- Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics (2013) (47)
- Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. (2011) (46)
- Reduced Plasma Level of CXC Chemokine Ligand 7 in Patients with Pancreatic Cancer (2010) (46)
- Immunotherapy for hepatocellular carcinoma: current status and future perspectives (2018) (46)
- Evaluation of the Therapeutic Effect of Transcatheter Arterial Embolization for Hepatocellular Carcinoma (2000) (46)
- Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer (2015) (45)
- Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. (2008) (44)
- EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. (2014) (44)
- Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein modification revealed by plasma proteomics. (2009) (44)
- Sex differences in oncogenic mutational processes (2019) (41)
- Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society (2019) (41)
- Altered Plasma Apolipoprotein Modifications in Patients with Pancreatic Cancer: Protein Characterization and Multi-Institutional Validation (2012) (41)
- C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer (2016) (40)
- Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON (2016) (40)
- Identification of a predictive biomarker for hematologic toxicities of gemcitabine. (2009) (40)
- Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future (2015) (39)
- Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (2013) (39)
- Abdominal Pain in Patients with Resectable Pancreatic Cancer with Reference to Clinicopathologic Findings (2001) (39)
- Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. (2017) (39)
- Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial. (2018) (38)
- Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma (2011) (38)
- A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis (2013) (38)
- Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization (2014) (38)
- Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial (2014) (37)
- Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma. (1997) (37)
- Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment* (2010) (37)
- Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial (2017) (37)
- Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease (2019) (37)
- Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent. (2009) (36)
- Phase I/II study of the pharmacokinetics, safety and efficacy of S‐1 in patients with advanced hepatocellular carcinoma (2010) (35)
- Ultrasound-guided percutaneous pancreatic tumor biopsy in pancreatic cancer: a comparison with metastatic liver tumor biopsy, including sensitivity, specificity, and complications (2008) (35)
- Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). (2006) (35)
- Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. (2011) (34)
- A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer† (2015) (34)
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial (2017) (33)
- Intratumoral DNA heterogeneity of small hepatocellular carcinoma (1995) (33)
- Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine (2017) (33)
- Spontaneous regression of hepatocellular carcinoma with multiple lung metastases: a case report. (2001) (32)
- Randomized, double‐blind, placebo‐controlled trial of bovine lactoferrin in patients with chronic hepatitis C (2006) (32)
- A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma (2011) (31)
- Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). (2016) (31)
- Past exposure to hepatitis B virus as a risk factor for hepatocellular carcinoma in patients with chronic liver disease. (1998) (31)
- Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated {alpha}-fetoprotein (AFP) from the randomized phase III REACH study. (2015) (30)
- Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial (2015) (29)
- Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. (1998) (29)
- Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry (2020) (28)
- The Usefulness of Serial Changes in Serum CA19-9 Levels in the Diagnosis of Pancreatic Cancer (2000) (28)
- Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines (2020) (28)
- ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer (2015) (28)
- Prevalence and predictive factors of depression and anxiety in patients with pancreatic cancer: a longitudinal study. (2016) (27)
- Improved survival with combined gemcitabine and S‐1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies (2014) (27)
- Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer (2020) (27)
- Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients (2018) (27)
- Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. (2002) (27)
- Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma (1998) (27)
- A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer (2007) (27)
- Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. (2016) (27)
- Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment? (2009) (27)
- Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. (2006) (26)
- A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. (2006) (26)
- His595Tyr polymorphism in the methionine synthase reductase (MTRR) gene is associated with pancreatic cancer risk. (2008) (26)
- Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2 (2020) (26)
- CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. (2019) (26)
- Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib (2014) (25)
- Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment (2010) (25)
- Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study (2018) (25)
- Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. (2011) (25)
- Systemic Chemotherapy for Pancreatic Cancer (2004) (24)
- 619OJET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma (2017) (24)
- Phase II Study of Cisplatin, Epirubicin, and Continuous-Infusion 5-Fluorouracil for Advanced Biliary Tract Cancer (2003) (24)
- Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases (2010) (24)
- A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC). (2019) (23)
- LBA16RAMUCIRUMAB (RAM) AS SECOND-LINE TREATMENT IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB: RESULTS FROM THE RANDOMIZED PHASE III REACH STUDY (2014) (23)
- Current status of hepatocellular carcinoma in Japan. (2013) (23)
- Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan (2014) (23)
- A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer (2009) (23)
- An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. (2017) (23)
- Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). (2018) (23)
- Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer (2017) (23)
- Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors (2015) (23)
- Prognosis of advanced pancreatic cancer patients with reference to calorie intake. (1998) (22)
- Predictive factors for recurrence after percutaneous ethanol injection for solitary hepatocellular carcinoma. (1996) (22)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- A Digest of the Pancreatic Cancer Registry Report 2007 (2009) (22)
- Cytotoxic chemotherapy for pancreatic neuroendocrine tumors (2015) (22)
- Phase I study of NK105, a paclitaxel-incorporating micellar nanoparticle, in patients with advanced cancer. (2006) (21)
- Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial. (2010) (21)
- Phase II Study of Uracil-Tegafur in Patients with Metastatic Pancreatic Cancer (2002) (21)
- Transcatheter Arterial Embolization with Zinostatin Stimalamer for Hepatocellular Carcinoma (2002) (21)
- JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis (2021) (21)
- TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC). (2021) (21)
- Spontaneous regression of hepatocellular carcinoma (2006) (21)
- Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma (2018) (20)
- Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK‐333 (2011) (20)
- Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. (1996) (20)
- Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506. (2009) (20)
- Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168). (2014) (20)
- Evaluation of acute intestinal toxicity in relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer. (2003) (19)
- Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) (2020) (19)
- A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma (2020) (19)
- Prospective Randomized Controlled Phase III Trial Comparing the Efficacy of Sorafenib versus Sorafenib in Combination with Low-Dose Cisplatin/Fluorouracil Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma (2016) (19)
- CT Evaluation of the progression of hypoattenuating nodular lesions in virus-related chronic liver disease. (2006) (19)
- Effect of Heavy Alcohol Intake on Long‐term Results after Curative Resection of Hepatitis C Virus‐related Hepatocellular Carcinoma (1996) (19)
- Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer (2018) (19)
- Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma (2001) (19)
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH). (2018) (18)
- Abstract CT061: A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results (2019) (18)
- A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial) (2020) (18)
- Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial (2020) (18)
- The prognosis of patients with hepatocellular carcinoma of multicentric origin. (1996) (18)
- Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials. (2020) (18)
- Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. (2018) (18)
- Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial (2019) (18)
- Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma (2015) (17)
- Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). (2008) (17)
- Targeted Therapy for Biliary Tract Cancer (2011) (17)
- Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis (2016) (17)
- Multiplexed single-molecule enzyme activity analysis for counting disease-related proteins in biological samples (2020) (17)
- Undifferentiated carcinoma of the liver with neuroendocrine features: a case report. (1998) (17)
- Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407). (2018) (17)
- A randomized study of gemcitabine/cisplatin versus single-agent gemcitabine in patients with biliary tract cancer. (2009) (17)
- Effect of percutaneous ethanol injection for postoperative recurrence of hepatocellular carcinoma in combination with transcatheter arterial embolization. (1996) (17)
- Chemoradiotherapy for Locally Advanced Pancreatic Carcinoma in Elderly Patients (2005) (17)
- Chemotherapy for biliary tract cancer in Japan. (2002) (16)
- Prognostic factors in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection (2002) (16)
- nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients (2020) (16)
- Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression (2017) (16)
- Serum tumor markers for pancreatic cancer: the dawn of new era? (2006) (16)
- Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data (2017) (16)
- Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy (2012) (15)
- Evidence for increased somatic cell mutations in patients with hepatocellular carcinoma. (1997) (15)
- Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426). (2014) (15)
- Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy (2018) (15)
- Landmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract cancer. (2020) (15)
- Hepatocellular carcinoma with gastrointestinal hemorrhage caused by direct tumor invasion to the duodenum. (1997) (15)
- Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805). (2012) (14)
- [Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355(miriplatin hydrate)--safety and efficacy in combination with embolizing agents]. (2010) (14)
- Hepatic Arterial Infusion Chemotherapy with Epirubicin in Patients with Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis (2007) (14)
- Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma. (2012) (14)
- Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma. (2008) (14)
- TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). (2019) (14)
- Clinicopathologic Features and Germline Sequence Variants in Young Patients (⩽40 Years Old) With Pancreatic Ductal Adenocarcinoma (2016) (14)
- Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis (2012) (14)
- A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies (2009) (14)
- A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. (2005) (14)
- Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry) (2018) (13)
- A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer. (2006) (13)
- First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors (2018) (13)
- Prognostic Factors in Patients with Hepatocellular Carcinoma Refractory or Intolerant to Sorafenib (2014) (13)
- Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease (2019) (13)
- Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials (2020) (13)
- Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805). (2010) (13)
- Radiotherapy for Hepatocellular Carcinoma (2000) (13)
- Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma (2002) (13)
- CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC). (2017) (12)
- Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents (2015) (12)
- Final result of a phase I/II trial of the oral anti-angiogenesis inhibitor TSU-68 in patients with advanced hepatocellular carcinoma (2008) (12)
- A phase II study of S-1 in patients with metastatic pancreatic cancer (2005) (12)
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH). (2018) (12)
- Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan (2016) (12)
- Interaction of natural killer cells with neutrophils exerts a significant antitumor immunity in hematopoietic stem cell transplantation recipients (2015) (12)
- Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy. (2014) (12)
- A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma (2017) (12)
- Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials (2017) (12)
- A phase II study of sequential methotrexate and 5-fluorouracil in metastatic pancreatic cancer. (2000) (11)
- Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results. (2013) (11)
- A review of changes to and clinical implications of the eighth TNM classification of hepatobiliary and pancreatic cancers. (2019) (11)
- Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial (2014) (11)
- Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer. (2007) (11)
- Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment (2017) (11)
- 742TiPPHASE 3 RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF CABOZANTINIB (XL184) VS PLACEBO IN SUBJECTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE RECEIVED PRIOR SORAFENIB (CELESTIAL) (NCT01908426). (2014) (11)
- Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population (2020) (11)
- 6502 A double-blinded, placebo-controlled, randomized, phase III study of axitinib (AG-013736; A) plus gemcitabine (G) vs. G plus placebo (P) in advanced pancreatic cancer (PC) patients (pts) (2009) (11)
- A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR). (2012) (10)
- Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. (2020) (10)
- A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE). (2015) (10)
- Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. (2021) (10)
- Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors (2017) (10)
- Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study. (2014) (10)
- Emerging drugs for biliary cancer (2014) (10)
- Antireflux Metal Stent for Initial Treatment of Malignant Distal Biliary Obstruction (2018) (10)
- A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 (2019) (10)
- 5-fluorouracil continuous infusion combined with cisplatin for advanced pancreatic cancer: a Japanese Cooperative Study. (1999) (10)
- Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer (2018) (10)
- PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay (2018) (10)
- Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213). (2015) (10)
- Clinical benefit of peretinoin for the suppression of hepatocellular carcinoma (HCC) recurrence in patients with Child-Pugh grade A (CP-A) and small tumor: A subgroup analysis in a phase II/III randomized, placebo-controlled trial. (2011) (10)
- Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. (2020) (10)
- Long-Term Results of High-Dose 2-Fraction Carbon Ion Radiation Therapy for Hepatocellular Carcinoma (2019) (10)
- A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class (2018) (10)
- Endoscopic ultrasound-guided hepaticogastrostomy or hepaticojejunostomy without dilation using a stent with a thinner delivery system (2020) (10)
- Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. (2020) (10)
- Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. (2005) (10)
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH). (2019) (9)
- FP therapy for controlling malignant ascites in advanced pancreatic cancer patients. (2007) (9)
- Gemcitabine-induced pleuropericardial effusion in a patient with pancreatic cancer. (2012) (9)
- Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer. (2005) (9)
- A randomized phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in comparison with zinostatin stimalamer in patients with hepatocellular carcinoma. (2009) (9)
- New approaches for pancreatic cancer in Japan (2004) (9)
- Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites. (2010) (9)
- Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma (2022) (9)
- Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis (2017) (9)
- Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomized trials. (2013) (8)
- Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study (2022) (8)
- Efficacy of radiotherapy for primary tumor in patients with unresectable pancreatic neuroendocrine tumors (2017) (8)
- Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study (2019) (8)
- A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. (2006) (8)
- What determines the timing of discussions on forgoing anticancer treatment? A national survey of medical oncologists (2018) (8)
- Everolimus versus placebo in Japanese patients with advanced pancreatic neuroendocrine tumors (pNET): Japanese subgroup analysis of RADIANT-3. (2011) (8)
- A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo (2017) (8)
- Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients (2012) (8)
- Guidance for peptide vaccines for the treatment of cancer (2014) (8)
- Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System (2022) (8)
- Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma. (2003) (8)
- Effect of biliary drainage on chemotherapy in patients with biliary tract cancer: an exploratory analysis of the BT22 study. (2012) (8)
- Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study (2015) (8)
- Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407). (2021) (8)
- Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. (2022) (7)
- Germline mutations in cancer-predisposition genes in patients with biliary tract cancer (2019) (7)
- Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. (2015) (7)
- Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma (2014) (7)
- Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy. (2017) (7)
- Hepatocellular carcinoma presenting with lung metastasis: Clinical characteristics and prognostic factors. (2009) (7)
- A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors (2022) (7)
- Multiple non‐tumorous arterioportal shunts due to chronic liver disease mimicking hepatocellular carcinoma: outcomes and the associated elevation of alpha‐fetoprotein (2006) (7)
- Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines (2018) (7)
- Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics (2013) (7)
- Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study (2017) (7)
- Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma (2022) (7)
- Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial (2023) (7)
- Erratum: Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer (2016) (7)
- Phase I study of TAC‐101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma (2012) (7)
- A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer. (2010) (7)
- Gemcitabine in Patients With Intraductal Papillary Mucinous Neoplasm With an Associated Invasive Carcinoma of the Pancreas (2013) (7)
- Current status of chemoradiotherapy for locally advanced pancreatic cancer in Japan (2008) (7)
- A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer (2007) (6)
- Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT (2021) (6)
- Phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer. (2016) (6)
- Phase II study of irinotecan (CPT-11) alone in patients (pts) with metastatic pancreatic cancer (2004) (6)
- Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma (2016) (6)
- The Diagnosis and Treatment of Pancreatic NEN-G3-A Focus onClinicopathological Difference of NET-G3 and NEC G3 (2018) (6)
- Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma (2012) (6)
- Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma (2014) (6)
- Novel endoscopic technique for tri-segment drainage in patients with unresectable hilar malignant biliary strictures (with video). (2020) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study) (2020) (6)
- Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. (2012) (6)
- Phase I Study of Hyperfractionated Radiation Therapy with Protracted 5-Fluorouracil Infusion in Patients with Locally Advanced Pancreatic Cancer (2004) (6)
- A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors (2019) (6)
- Chemotherapy for patients with unresesctable pancreatic cancer is recommended in the Clinical Practice Guidelines for Pancreatic Cancer 2019 (2020) (6)
- A retrospective analysis of factors associated with selection of end-of-life care and actual place of death for patients with cancer (2014) (6)
- O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma (2020) (5)
- Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2) (2019) (5)
- The Role of EUS and EUS-FNA in Differentiating Benign and Malignant Gallbladder Lesions (2021) (5)
- Fine‐needle biopsy with 19G needle is effective in combination with endoscopic ultrasound‐guided tissue acquisition for genomic profiling of unresectable pancreatic cancer (2022) (5)
- Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer (2016) (5)
- Integrated communication support program for oncologists, caregivers and patients with rapidly progressing advanced cancer to promote patient-centered communication: J-SUPPORT 1904 study protocol for a randomised controlled trial (2020) (5)
- Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25]. (2018) (5)
- The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG): history and future direction. (2013) (5)
- 217 Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma (2014) (5)
- Novel simultaneous endoscopic ultrasound-guided hepaticoduodenostomy and hepaticogastrostomy for recurrent hepatic hilar obstruction (2018) (5)
- Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL) (2019) (5)
- Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an Anti–Interleukin-6 Receptor Monoclonal Antibody, Combined with Gemcitabine in Patients with Advanced Pancreatic Cancer (2017) (5)
- Prolyl 4-Hydroxylation of α-Fibrinogen (2009) (5)
- A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization (2008) (5)
- FINAL RESULTS OF A PHASE II STUDY OF S-1 IN PATIENTS WITH METASTATIC PANCREATIC CANCER (2006) (5)
- 56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC) (2022) (5)
- Hemorrhage from Ascending Colon and Gluteal Muscle Associated with Sorafenib and Radiation Therapy: Radiation Dose Distribution Corresponded with Colonoscopy Findings and Computed Tomography Images. (2019) (5)
- Endoscopic ultrasound-guided gastroenterostomy using a metal stent for the treatment of afferent loop syndrome (2019) (5)
- A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors (2015) (5)
- Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives (2021) (5)
- Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies (2022) (5)
- [Tumor markers for pancreatic and biliary tract cancer]. (2004) (4)
- One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry. (2021) (4)
- A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer. (2019) (4)
- Proportion of unresectable pancreatic cancer specimens obtained by endoscopic ultrasound-guided tissue acquisition meeting the OncoGuide™ NCC Oncopanel System analysis suitability criteria: a single-arm, phase II clinical trial (2022) (4)
- Successful Everolimus Treatment in a Patient with Advanced Pancreatic Neuroendocrine Tumor Who Developed Everolimus-Induced Interstitial Lung Disease on Two Occasions: A Case Report (2013) (4)
- Symptom changes that predict disease control by systemic chemotherapy in patients with advanced pancreatic cancer. (2012) (4)
- Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer (2020) (4)
- Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an AntiâÂÂInterleukin-6 Receptor Monoclonal Antibody, Combined with Gemcitabine in Patients with Advanced Pancreatic Cancer (2017) (4)
- Chemoradiotherapy versus gemcitabine-based chemotherapy in patients with unresectable, locally advanced pancreatic cancer. (2010) (4)
- Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study (2019) (4)
- CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC) - Trial in progress. (2018) (4)
- Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment (2016) (4)
- A multicenter phase II study of gemcitabine (GEM) in patients with unresectable biliary tract cancer (2005) (4)
- Functional Characterization of the Effects of N-acetyltransferase 2 Alleles on N-acetylation of Eight Drugs and Worldwide Distribution of Substrate-Specific Diversity (2021) (4)
- Prognosis of hepatocellular carcinoma with no tumor stain treated by percutaneous ethanol injection. (2001) (4)
- Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma (2019) (4)
- 2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment (2015) (4)
- A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma. (2018) (4)
- Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). (2019) (4)
- 6590 A phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer (2009) (4)
- SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. (2018) (3)
- Effect of cytidine deaminase (CDA)-related biomarkers on overall survival in patients with advanced pancreatic cancer receiving gemcitabine (GEM) monotherapy. (2011) (3)
- Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. (2021) (3)
- CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC). (2017) (3)
- Details of HER2 status in 454 cases of biliary tract cancer. (2020) (3)
- A phase I study of GC33 in Japanese patients with advanced hepatocellular carcinoma (HCC). (2013) (3)
- Meta-analysis of randomized phase II and phase III trials of gemcitabine with/without S-1 in Asian patients with advanced pancreatic cancer. (2012) (3)
- Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy (2019) (3)
- 1466P Napabucasin + nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study (2021) (3)
- Phase I study of safety, pharmacokinetics, and efficacy of TSU-68 plus S-1 combination in patients with advanced hepatocellular carcinoma. (2013) (3)
- Phase II study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC). (2008) (3)
- Re-intervention for recurrent biliary obstruction after endoscopic ultrasound hepaticogastrostomy with partially covered self-expandable metal stent (2019) (3)
- Phase II study of irinotecan (CPT-11) alone in patients (pts) with metastatic pancreatic cancer. (2004) (3)
- Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial. (2015) (3)
- Duckbill-type antireflux self-expandable metal stent placement for post-choledochojejunostomy reflux cholangitis (2020) (3)
- A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer (2021) (3)
- Successful control of intractable hypoglycemia using radiopharmaceutical therapy with strontium-89 in a case with malignant insulinoma and bone metastases. (2012) (3)
- Enormous Potential of Endoscopic Ultrasound-guided Liver Biopsies (2020) (3)
- Predictive factors for tumor response to chemotherapy in patients with pancreatic cancer. (2000) (3)
- Phase II/III clinical trial with VEGFR2-epitope peptide and gemcitabine for patients with locally advanced, metastatic, or unresectable pancreatic cancer: Pegasus-PC study. (2013) (3)
- 2382 A proof-of-concept study of MEK inhibitor trametinib monotherapy in patients with biliary tract cancers (2015) (3)
- Retrospective comparison of modified FOLFIRINOX with full-dose FOLFIRINOX for advanced pancreatic cancer: A Japanese cancer center experience. (2018) (3)
- Quality of life (QOL) evaluation within a randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable, advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. (2011) (3)
- Study Protocol of the Japan NEN Registry: A Multicenter, Prospective Registry of Patients with Pancreatic, Gastrointestinal, Pulmonary, Bronchial, and Thymic Neuroendocrine Neoplasm (2019) (3)
- Phase II study of sunitinib (SU) in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (NET). (2012) (3)
- Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). (2018) (3)
- Treatment for postoperative recurrence of pancreatic cancer: a narrative review. (2021) (3)
- Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (LAPC): Final analysis of JCOG1106 (2016) (3)
- Usefulness of the laser‐cut, fully covered, self‐expandable metallic stent for endoscopic ultrasound‐guided hepaticogastrostomy (2022) (3)
- Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade (2016) (3)
- Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis (2019) (2)
- Clinical characteristics of pancreatic and biliary tract cancers associated with Lynch syndrome (2021) (2)
- Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) (2020) (2)
- O2-16-6Comparative effectiveness of gemcitabine vs gemcitabine+nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer (2017) (2)
- O-005Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study (2015) (2)
- Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer (2019) (2)
- Assessing the need for a question prompt list that encourages end-of-life discussions between patients with advanced cancer and their physicians: A focus group interview study – ERRATUM (2021) (2)
- Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines (2019) (2)
- 769TiPRandomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG1407) (2017) (2)
- Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? (2015) (2)
- Genome-wide association meta-analysis identifies novel GP2 gene risk variants for pancreatic cancer in the Japanese population (2018) (2)
- Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology (2016) (2)
- [Non-surgical treatment for pancreatic cancer]. (2006) (2)
- A randomized phase III trial comparing adjuvant chemotherapy with S-1 vs. surgery alone in patients with resectable biliary tract cancer (JCOG1202: ASCOT). (2017) (2)
- Prediction of tissue-of-origin of early stage cancers using serum miRNomes (2022) (2)
- Clinical significance of serum alkaline phosphatase level in advanced pancreatic cancer. (2011) (2)
- Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial. (2016) (2)
- A multicenter phase II trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. (2010) (2)
- Use of endoscopic ultrasound‐guided biliary drainage as a rescue of re‐intervention after the placement of multiple metallic stents for malignant hilar biliary obstruction (2021) (2)
- Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study. (2015) (2)
- P2–094PHASE II STUDY OF SUNITINIB (SU) IN JAPANESE PATIENTS WITH WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMOR (NET) (2013) (2)
- SY1. building the foundation for investigator-initiated clinical trial (2012) (2)
- Clinicopathological features in misdiagnosed pancreatic carcinoma. (1999) (2)
- Novel biliary drainage of a choledochojejunal anastomotic stenosis using a double-balloon endoscope and forward-viewing endoscopic ultrasound (2020) (2)
- 1236 POSTER Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of the Multikinase Inhibitor Regorafenib (BAY 73-4506) in Japanese Patients With Advanced Solid Tumours (2011) (2)
- Phase II study of hyperfractionated radiotherapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer (2005) (2)
- Phase III Trial of Everolimus in Advanced Pancreatic Neuroendocrine Tumors (RADIANT-3): Overall Population and Japanese Subgroup Analysis (2012) (2)
- A conundrum for randomized controlled trials: experience from a small hepatocellular carcinoma trial. (2010) (2)
- P-122Phase I study of S-1, irinotecan plus oxaliplatin combination therapy (S-IROX) for Unresectable pancreatic ductal adenocarcinoma (2016) (2)
- [Immune checkpoint inhibitors in hepatocellular carcinoma]. (2019) (2)
- Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC) (2019) (2)
- A phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis (2008) (2)
- TAS-118 (S-1 plus leucovorin) versus S-1 in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, phase III trial (GRAPE trial). (2017) (2)
- Endoscopic ultrasound‐guided choledochoduodenostomy without fistula dilation using a stent with a 5.9‐Fr delivery system: Comparison to a conventional procedure with fistula dilation (2021) (2)
- Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. (2019) (2)
- Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (JCOG1106). (2015) (2)
- Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience (2020) (2)
- 689PGENE MUTATION PROFILE OF PANCREATIC CANCER OBTAINED USING TARGETED DEEP SEQUENCING AND ITS ASSOCIATION WITH PROGNOSIS. (2014) (1)
- A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced hepatocellular carcinoma (HCC). (2014) (1)
- O2-9-5GENE MUTATION PROFILE OF PANCREATIC CANCER IN JAPANESE PATIENTS AND ITS ASSOCIATION WITH PROGNOSIS (2014) (1)
- Transarterial infusion chemotherapy alone versus transarterial chemoembolization for the treatment of hepatocellular carcinoma: Results of a multicenter randomized phase III trial (2007) (1)
- First-in-man combination phase I study of TAS-114 and S-1 in patients (pts) with advanced solid tumors. (2015) (1)
- Phase 1 studies of 3- and 6-peptide vaccine cocktail derived from GPC3, WDRPUH, and NEIL3 in patients with advanced hepatocellular carcinoma (HCC). (2018) (1)
- P-167Risk factors for febrile neutropenia in patients with unresectable pancreatic cancer receiving FOLFIRINOX as the first-line treatment (2015) (1)
- Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial (2014) (1)
- Endoscopic ultrasound-guided hepaticoduodenostomy with anterograde stenting for recurrent hepatic hilar obstruction (2021) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Incidence and risk factors for cholangitis during systemic chemotherapy among patients with advanced biliary tract cancer. (2011) (1)
- A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy. (2018) (1)
- A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma (2020) (1)
- Atezolizumab-induced Encephalitis in a Patient with Hepatocellular Carcinoma: A Case Report and Literature Review (2022) (1)
- 704PFINAL SAFETY ANALYSIS OF ERLOTINIB PLUS GEMCITABINE IN A POST-MARKETING SURVEILLANCE STUDY (POLARIS) OF >800 JAPANESE PANCREATIC CANCER PATIENTS. (2014) (1)
- Association of interleukin-6 levels and neutropenia during gemcitabine monotherapy for advanced pancreatic cancer. (2011) (1)
- Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies. (2016) (1)
- Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world (2022) (1)
- Medical oncologists attitude toward end-of-life discussions: Effects of their experience, perceptions, and beliefs. (2015) (1)
- Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan. (2012) (1)
- Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan (2022) (1)
- Evaluation of the ideal pancreatic cancer classroom: Report on the status of activities at nine major institutions (2020) (1)
- The association of long pentraxin 3 on prognosis in pancreatic carcinoma patients on gemcitabine-based chemotherapy. (2011) (1)
- Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy (2012) (1)
- Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial. (2022) (1)
- Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study). (2020) (1)
- A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. (2011) (1)
- Multicenter randomized phase II study comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer: PAN-01 study. (2016) (1)
- The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry (2022) (1)
- Development of quality indicators for liver cancer care (2008) (1)
- Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score. (2015) (1)
- Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment (2013) (1)
- [Chemotherapy for hepatocellular carcinoma]. (2004) (1)
- Novel endoscopic ultrasound-guided hepaticoduodenostomy using a forward-viewing echoendoscope for altered anatomy (2020) (1)
- Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC). (2021) (1)
- Association of SNPs in ABCC1 gene with overall survival in stage IV pancreatic adenocarcinoma patients treated with gemcitabine monotherapy (2008) (1)
- Outcome and cause of death of hepatocellular carcinoma patients with extrahepatic metastases. (2015) (1)
- 196 The efficacy, toxicity and pharmacokinetic findings of S-1 in patients (pts) with advanced biliary tract cancer (BTC): a phase II trial (2003) (1)
- Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis (2012) (1)
- A video to initiate advance care planning: The development of educational and supportive materials for patients with pancreatic and biliary tract cancer (2020) (1)
- Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials (2019) (1)
- Phase I trial of gemcitabine and Wilms' tumor 1 peptide vaccine combination therapy in patients with advanced pancreatic or biliary tract cancer. (2010) (1)
- A pooled analysis of long pentraxin for patients with advanced pancreatic cancer. (2016) (1)
- Novel forward-viewing EUS-guided ileoureterostomy technique for recurrent pyelonephritis caused by ureteral stenosis (2018) (1)
- Impact of cytidine deaminase genetic polymorphisms on gemcitabine kinetics and toxicity in Japanese cancer patients (2005) (1)
- 6587 POSTER A Phase 1b, Open-Label Study to Evaluate the Safety of Ganitumab (AMG 479) in Combination With Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer (2011) (1)
- Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC) (2016) (1)
- [Trends of epidemiology of pancreatic endocrine tumors: a nationwide survey analysis in Japan]. (2015) (1)
- First-in-man phase 1 study of TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors (2016) (1)
- 6610 Hepatocellular carcinoma presenting with lung metastasis: clinical characteristics and prognostic factors (2009) (1)
- Study protocol for a multi-institutional prospective surveillance study among kindreds with familial pancreatic cancer and individuals with hereditary pancreatic cancer syndrome: The Diamond Study. (2022) (1)
- 68P A phase Ib study of lenvatinib + pembrolizumab (LEN + PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis (2021) (1)
- Phase I study of gemcitabine and S-1 combination therapy in patients with advanced pancreatic cancer (2004) (1)
- SMANCS: a clinical review (2004) (1)
- Corrigendum to: Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry (2020) (1)
- Efficacy of chemotherapy in patients with recurrent pancreatic cancer. (2017) (1)
- Phase I/II Trial of Lenvatinib (E7080), A Multi-Targeted Tyrosine Kinase Inhibitor, in Patients (PTS) with advanced Hepatocellular Carcinoma (HCC) (2012) (1)
- Cholangiocarcinoma: is it time for a revolution? (2021) (1)
- The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer (2022) (1)
- A novel endoscopic technique using fully covered self-expandable metallic stents for benign strictures after hepaticojejunostomy: the saddle-cross technique (with video) (2022) (1)
- A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors (2022) (1)
- A randomized controlled trial with a cluster of oncologists evaluating of an integrated communication support program for oncologists, caregivers, and patients with rapidly progressing advanced cancer on patient-centered conversation: J-SUPPORT 1704 study. (2021) (1)
- Randomized Phase II Trial of S-1 versus S-1 Plus Oxaliplatin (SOX) in Patients with Gemcitabine Refractory Pancreatic Cancer (2012) (1)
- Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice (2022) (1)
- A phase III, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine (G) as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial. (2012) (1)
- The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 (2022) (1)
- Assessing the need for a question prompt list that encourages end-of-life discussions between patients with advanced cancer and their physicians: A focus group interview study (2022) (1)
- A case of pancreatic cancer achieving symptomatic improvement with systemic chemotherapy. (1999) (1)
- Phase I study of ontuxizumab, a humanized monoclonal antibody (mAb) recognizing endosialin in Japanese patients (pts) with hepatocellular carcinoma (HCC). (2015) (1)
- Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis (2023) (1)
- 508 POSTER Association of genetic polymorphisms with survival in Japanese pancreatic cancer patients treated with gemcitabine (2007) (1)
- Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer (2021) (1)
- Endoscopic ultrasound-guided choledochoduodenostomy without fistula dilation using a novel fully covered metallic stent with a 5.9-Fr ultra-thin delivery system (2020) (1)
- Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al. (2017) (1)
- A Multi-Center Phase II Study of Intra-Arterial Chemotherapy of a Fine-Powder Formulation of Cisplatin in Patients with Advanced Intrahepatic Cholangiocarcinoma (2012) (0)
- Abstract 4580: Detection of early-stage pancreatic cancer by mass spectrometry: a multi-institutional validation study (2010) (0)
- First line and second-third line treatment outcome by concurrent chemoradiotherapy with S-1 for locally advanced pancreatic cancer (2016) (0)
- Efficacy of an educational program for patients with pancreatic and biliary cancers, and their caregivers. (2017) (0)
- Correction to: Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world (2022) (0)
- Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an Anti–Interleukin-6 (2017) (0)
- Mo1193 Endoscopic Covered Metal Stent Placement for Hemorrhagic Duodenal Stenosis Due to Invasion by Biliary or Pancreatic Cancer (2017) (0)
- Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases (2019) (0)
- Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer (2019) (0)
- Subject Index Vol. 59, 2000 (2000) (0)
- IS2-4CURRENT STATUS AND PERSPECTIVE OF CHEMOTHERAPY FOR UNRESECTABLE PANCREATIC NEUROENDOCRINE CARCINOMA (2014) (0)
- Impact of renal function on the efficacy and safety of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. (2019) (0)
- Phase II trial of chemoradiotherapy using weekly gemcitabine (GEM) in patients (pts) with locally advanced pancreatic cancer (PC). Final results (2004) (0)
- The factors associated with the malignant nature in Japanese patients with pNETs: Data from a nationwide survey (2016) (0)
- 6574 POSTER Thirty-four Cases of Advanced Ampullary Carcinoma Receiving Non-surgical Treatment – Experience at a Single Center (2011) (0)
- 64P Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE) (2022) (0)
- [Multifaceted Intervention to Explore the Appropriate Time of Anti-Cancer Treatment Cessation]. (2016) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- P-103Prognostic factors for survival in patients with advanced intrahepatic cholangiocarcinoma treated with gemcitabine plus cisplatin as first line treatment (2016) (0)
- Contents Vol. 58, 2000 (2000) (0)
- Impact of chronic hepatitis virus infection on the feasibility and efficacy for Asian patients with hepatocellular carcinoma in phase I clinical trials (2018) (0)
- Contents Vol. 92, 2017 (2017) (0)
- Efficacy markers for cisplatin and S-1 in biliary tract carcinoma. (2015) (0)
- [Palliative therapy in patients with biliary tract cancer]. (2006) (0)
- Endoscopic ultrasound-guided intra-afferent loop entero-enterostomy using a forward-viewing echoendoscope and insertion of a metal stent (2022) (0)
- Clinicopathologic and germline mutation analysis of young patients (age 40 and younger) with pancreatic ductal adenocarcinoma. (2015) (0)
- Pancreatic neuroendocrine tumors: Twenty years' experience of 100 patients at a single center. (2012) (0)
- Comparison of clinical features by primary sites in patients with biliary tract cancer who received gemcitabine-based chemotherapy: An exploratory analysis of JCOG1113. (2023) (0)
- Interim safety analysis of a randomized phase II trial comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with advanced pancreatic cancer (2015) (0)
- Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113 (2021) (0)
- 747PPhase I study of resminostat/S-1 combination in patients with pre-treated biliary tract or pancreatic cancer (2017) (0)
- A phase II trial of continuous-infusion 5-fluorouracil, mitoxantone and cisplatin for metastatic hepatocellular carcinoma. (2004) (0)
- The correlation between the decrease of intratumoral arterial enhancement and time-to-tumor progression in patients with hepatocellular carcinoma treated with sorafenib. (2011) (0)
- Phase I Study of FixedDoseRate Infusion ofGemcitabine in Patients with Unresectable Pancreatic Cancer (2005) (0)
- [Current status and future directions in chemotherapy for biliary tract carcinoma]. (2015) (0)
- Expanded Treatment Efficacy and Safety Study of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Epirubicin/ Doxorubicin–Lipiodol Emulsion and Gelatin Particles: A Cooperative Study between Korea and Japan (2012) (0)
- Activities of an educational program for patients with pancreatic cancer and their caregivers (2016) (0)
- [Medical treatment of pancreatic neuroendocrine tumor]. (2011) (0)
- Novel side-by-side metal stent placement for recurrent hepatic hilar obstruction after placement of multiple metal stents (2020) (0)
- Nal-IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer: Additional safety report of randomized Japanese phase 2 trial. (2022) (0)
- Study on deep vein thrombosis (DVT) risk factors at the time of cancer diagnosis in patients from the multicenter, prospective Cancer-Venous Thromboembolism (VTE) Registry. (2020) (0)
- Longitudinal comparisons of results in surgical resection and percutaneous ethanol injection therapy (PEI): Change in treatment strategy for small hepatocellular carcinoma (HCC). (2004) (0)
- Contents Vol. 64, 2003 (2003) (0)
- NOVEL PROTEIN MODIFICATION-Fibrinogen : A α Prolyl 4-Hydroxylation of Modification , and Degradation : Protein Synthesis , Post-Translational (2009) (0)
- [Systemic chemotherapy and chemoradiotherapy for advanced pancreatic cancer]. (2012) (0)
- Use of a genome-wide association study to detect candidate polymorphisms associated with overall survival in stage IV pancreatic adenocarcinoma patients receiving gemcitabine monotherapy. (2009) (0)
- 9128 Advanced poorly differentiated neuroendocrine carcinoma arising from miscellaneous organs was less sensitive to chemotherapy and had poorer prognosis than advanced small-cell lung carcinoma (2009) (0)
- [Progression of chemotherapy]. (2011) (0)
- AB029. S6-3. Clinical trials incorporating translational targets (2019) (0)
- P-119Chemoradiotherapy versus chemotherapy alone for unresectable locally advanced pancreatic cancer: a retrospective cohort study (2016) (0)
- Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma (2016) (0)
- [The excision repair cross-complementation group 1]. (2015) (0)
- A novel triple stenting in the treatment of post-choledochojejunostomy reflux cholangitis (2022) (0)
- Abstract 393: Clinical impact of pentraxin family expression on prognosis in pancreatic carcinoma. (2013) (0)
- [Availability of Palliative Care Units and Outpatient Services in Japan - A Nation-Wide Survey]. (2015) (0)
- Successful case of cholangioscope‐assisted extraction of a radiolucent intrahepatic bile duct stent (2019) (0)
- Construction and validation of a practical prognostic index for patients with metastatic pancreatic adenocarcinoma. (2011) (0)
- Phase I and pharmacokinetic study of 5-fluorouracil (5-FU) 5-day continuous infusion in hepatocellular carcinoma (HCC) patients with liver cirrhosis (LC) (1998) (0)
- Identification of prognostic factors for patients with advanced pancreatic cancer by proteomics. (2009) (0)
- Impact of bodyweight (BW)-based starting doses on safety and efficacy of lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC). (2021) (0)
- Issues in the 2019 revision of the Clinical Practice Guidelines for pancreatic cancer - Supportive/palliative care (2020) (0)
- ISS1-3-4Final phase II results for sunitinib (SU) in Japanese pts with well-differentiated pancreatic neuroendocrine tumor (NET) (2015) (0)
- 6595 POSTER Phase I Study of Gemcitabine as a Fixed Dose Rate Infusion and S-1 Combination Therapy (FGS) in Gemcitabine-refractory Biliary Tract Cancer (BTC) Patients (2011) (0)
- 409 Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies against apolipoprotein-AII isoforms (2015) (0)
- [Pancreatic tumor: progress in diagnosis and treatment. Topics: I. Pancreatic carcinoma; 4. Progress of non-surgical treatment for pancreatic cancer]. (2012) (0)
- SY11-2ADJUVANT CHEMOTHERAPY FOR RESECTED PANCREATIC CANCER: FOCUSING ON THE JSAP STUDY (2014) (0)
- 754PImpact of the duration of diabetes mellitus (DM) on the outcomes of metastatic pancreatic cancer (mPC) treated with gemcitabine (G): A retrospective study (2017) (0)
- PD-8 Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study (2022) (0)
- The 2019 revision of the Clinical Practice Guidelines for pancreatic cancer -General remarks (2020) (0)
- [A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer]. (2015) (0)
- Phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer (2019) (0)
- OS1. gastric cancer (2012) (0)
- Abstract 4484: HER3 expression after systemic therapy and clinical characteristics in patients with hepatocellular carcinoma (2023) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- A case of pathological complete response after combination chemotherapy by sorafenib and cisplatin hepatic arterial infusion for an advanced hepatocellular carcinoma (2013) (0)
- ISY-12-1Current status of biotherapies and chemotherapies for GEP-NETs (2016) (0)
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular (2015) (0)
- Transarterial infusion chemotherapy with cisplatin plus S-1 for treating hepatocellular carcinoma: Results of a phase I trial. (2012) (0)
- [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma]. (2012) (0)
- M1562 Diagnosis and Treatment of Early Pancreatic Cancer. from Nation-Wide Pancreatic Registry (2009) (0)
- SY-2-1Evidence of reactivation of hepatitis B virus in patients receiving chemotherapy for malignancies (2016) (0)
- Relations of QOL to Tumor Response and Adverse Events in Unresectable advanced Pancreatic Cancer Patients in the Gest Study (2012) (0)
- DEVELOPMENT OF STRATEGIES FOR NON-SURGICAL TREATMENT IN PANCREATIC CANCER (2007) (0)
- The influence of major hepatectomy on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subset analysis of JCOG1113. (2022) (0)
- Neuroendocrine Tumor: Molecular-Targeting Therapy for PNET (2012) (0)
- Perspectives in Therapy for Pancreatic Neuroendocrine Carcinomas (2009) (0)
- The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 (2022) (0)
- Risk factors for early relapse in patients with biliary tract cancers who underwent curative resection: An exploratory subgroup analysis of JCOG1202. (2023) (0)
- 4. Molecularly Targeted Agent (2014) (0)
- Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer (2020) (0)
- Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study (2018) (0)
- O2–018A RETROSPECTIVE ANALYSIS OF LONG-TERM SURVIVORS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (2013) (0)
- Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial (2022) (0)
- MIS5. hepato-biliary-pancreatic (2012) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Objective Response by mRECIST is an Independent Prognostic Factor for overall Survival in Hepatocellular Carcinoma in SILIUS Trial (2019) (0)
- Contents Vol. 68, 2005 (2005) (0)
- Novel and safe plastic stent exchange method after endoscopic ultrasound-guided hepaticogastrostomy with incomplete fistula (side hole method) (2022) (0)
- A case of high grade pancreatic intraepithelial neoplasia diagnosed by endoscopic ultrasound-guided fine needle aspiration. (2022) (0)
- 3553 POSTER Phase I/II study of S-1 in patients (pts) with advanced hepatocellular carcinoma (HCC): Results of phase I part – Correlation between pharmacokinetics (PK) and hepatic dysfunction (2007) (0)
- 501 Immunological STAT3 knockdown associated with anti-tumor activity in pre-clinical models translates to clinical samples, suggesting immune modulation contributes to the clinical activity of AZD9150, a therapeutic STAT3 ASO (2014) (0)
- Strategy for treatment of a nonfunctioning pancreatic neuroendocrine neoplasm with liver metastases (2015) (0)
- O1–035CLINICAL FEATURES AND OUTCOME OF HEPATOCELLULAR CARCINOMA PATIENTS WITHOUT ETIOLOGIC RISK FACTORS (2013) (0)
- Long-Term Administration of Wilms Tumor-1 Peptide Vaccine in Combination with Gemcitabine Causes Severe Local Skin Inflammation at Injection Sites (2010) (0)
- Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience (2022) (0)
- Endoscopic ultrasound-guided hepaticojejunostomy for drainage of the right posterior hepatic duct enabled total liver drainage (2023) (0)
- [Ⅱ. Chemotherapy: Current Status of Development of Chemotherapy for Biliary Tract and Pancreatic Cancers]. (2022) (0)
- Phase I/II study of FGF401 in adult patients (pts) with hepatocellular carcinoma (HCC) or solid tumors and positive FGFR4/KLB expression (2017) (0)
- Phase I study of gemcitabine and S-1 combination therapy in patients with advanced pancreatic cancer. (2004) (0)
- Progress in Drug Treatment for Hepatobiliary and Pancreatic Cancer. (2017) (0)
- Transarterial Infusion Chemotherapy with Cisplatin Plus S-1 for Treating Hepatocellular Carcinoma: Results of a Phase I Trial (2012) (0)
- Study Protocol for Prospective Observational Study 1 on the Prognosis of Patients with Unresectable Advanced Gastrointestinal and Pancreatic Neuroendocrine Tumors (PROP-UP 1 Study) in Japan (2018) (0)
- Clinical benefit response of concurrent chemoradiotherapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer (1998) (0)
- EL1The latest evidence of pharmacotherapies in Pancreatic Neuroendocrine Tumors (PNETs) (2015) (0)
- Effect of inflammatory and nutritional (IN) status on induction chemotherapy (CT) followed by chemoradiotherapy (CRT) for locally advanced pancreatic cancer (LAPC): An exploratory subgroup analysis of JCOG1106. (2017) (0)
- Association of hypophosphatemia-occurring sorafenib with prognosis and hepatic impairment in patients with advanced hepatocellular carcinoma. (2011) (0)
- Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples (2022) (0)
- Changes in the level of knowledge and distress in patients with pancreaticobiliary cancer and their caregivers after receiving information from an educational program (2021) (0)
- ISY-21-2Current status of FOLFIRINOX in Japan: modified or original? (2016) (0)
- A comparison of the guidelines for pancreatic cancer in Japan and the United States (2021) (0)
- Abstract 3405: Changes in HER3 expression associated with chemotherapy for pancreatic cancer (2023) (0)
- Tu1533 - Synergistic Effectes of Gemcitabine and Cisplatin in 17 Biliary Tract Cancer Cell Lines (2018) (0)
- [Tumor markers in biliary tract cancer]. (2006) (0)
- Comparison of the hybrid and partial stent-in-stent method for endoscopic three-segment drainage for unresectable malignant hilar biliary obstruction (2022) (0)
- A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). (2022) (0)
- Phase I study of nivolumab or nivolumab/cisplatin/gemcitabine to treat unresectable/recurrent biliary tract cancer (2019) (0)
- Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials (2017) (0)
- Subject Index Vol. 68, 2005 (2005) (0)
- Gamma (Gemcitabine and Amg 479 for Metastatic Adenocarcinoma of the Pancreas): a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Ganitumab Plus Gemcitabine (G) or Placebo Plus G as First-Line Therapy for Metastatic Pancreatic Cancer (2012) (0)
- [S-1 monotherapy for pancreatic cancer]. (2006) (0)
- [Adverse event and countermeasure with regard to FOLFIRINOX for pancreatic cancer]. (2015) (0)
- The outcomes of endoscopic ultrasound-guided fine needle aspiration and neoadjuvant chemotherapy for patients with resectable pancreatic cancer (2021) (0)
- [Liver cancer: progress in diagnosis and treatments. Topics: VI. Progress in treatments of liver cancer; 4. Molecularly targeted agent]. (2014) (0)
- Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial (2023) (0)
- 221PPhase I study of S-1, irinotecan plus oxaliplatin combination therapy for advanced pancreatic cancer (2015) (0)
- Troubleshooting for endoscopic ultrasound-guided hepaticogastrostomy stent migration: Additional stenting by the partial stent-in-stent method (2022) (0)
- Usefulness of a laser-cut covered metal stent with a 7F delivery sheath in endoscopic ultrasound-guided biliary drainage without fistula dilation (2022) (0)
- Contents, Vol. 51, 1994 (1993) (0)
- ISY2-2Adjuvant and neoadjuvant therapy for resectable pancreatic cancer (2015) (0)
- Novel double endoscopic ultrasound-guided hepaticogastrostomy for two-hole benign anastomotic stenosis with difficult gastrointestinal approach (2020) (0)
- Preference of end-of-life discussion at diagnosis in patients with advanced/recurrent cancer. (2017) (0)
- MO9-2 Usefulness of EUS-FNA for diagnosis of intraperitoneal tumors other than hepatobiliary and pancreatic cancer (2022) (0)
- The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113. (2019) (0)
- 2356 Phase I dose-escalation study of nintedanib in Japanese patients with advanced hepatocellular carcinoma (HCC) and mild or moderate liver impairment (2015) (0)
- Real-world data in 1000 patients with unresectable hepatocellular carcinoma (HCC) treated with systemic therapy: Patient background in PRISM study. (2023) (0)
- Phase II trial of chemoradiotherapy using weekly gemcitabine (GEM) in patients (pts) with locally advanced pancreatic cancer (PC). Final results. (2004) (0)
- Subject Index, Vol. 51, 1994 (1994) (0)
- The oncologists' views toward end-of-life discussions (2016) (0)
- O1-17-3Safety and efficacy of modified FOLFIRINOX in patients with metastatic pancreatic cancer (2015) (0)
- Electronic patient-reported outcome measured in patients with pancreatic cancer receiving second-line chemotherapy: A multicenter prospective observational study. (2023) (0)
- Randomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT). (2023) (0)
- Contents Vol. 59, 2000 (2000) (0)
- O2-8-1Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial (2015) (0)
- P-120Gemcitabine + nab-paclitaxel as first-line chemotherapy for Japanese patients with advanced pancreatic cancer in real-world clinical practice: a retrospective study (2016) (0)
- PhaseIStudyofFixedDoseRateInfusionofGemcitabineinPatients with Unresectable Pancreatic Cancer (2005) (0)
- Short communication Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma (2003) (0)
- O2-13-4EFFICACY AND POSSIBLE BIOMARKER OF GEMCITABINE AND ERLOTINIB FOR ADVANCED PANCREATIC CANCER (2014) (0)
- A Phase II Trial of Gemcitabine for Chemo-Naive Metastatic Pancreatic Endocrine Tumor (2012) (0)
- A feasibility study of a peer discussion group intervention for patients with pancreatobiliary cancer and their caregivers (2021) (0)
- Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreaticobiliary Cancer Aiming for a Comprehensive Genome Profile (2023) (0)
- The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan (2022) (0)
- Geriatric assessment and management with question prompt list using a web-based application for elderly patients with cancer (MAPLE) to communicate ageing-related concerns: J-SUPPORT 2101 study protocol for a multicentre, parallel group, randomised controlled trial (2022) (0)
- 6623 Cisplatin plus etoposide as first-line chemotherapy for poorly- differentiated neuroendocrine carcinoma of the hepatobiliary and pancreatic region (2009) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- 3544 POSTER Phase I study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy in gemcitabine-refractory pancreatic cancer patients. (2007) (0)
- A phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) for advanced hepatocellular carcinoma. (2010) (0)
- Indication for local ablation therapy for small HCC with reference to intrahepatic metastasis (2001) (0)
- How should pain be controlled in clinical trials for pancreatic cancer (1996) (0)
- The second nationwide survey of gastroenteropancreatic neuroendocrine tumors in Japan (2013) (0)
- Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (2019) (0)
- Author Correction: The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan (2022) (0)
- Contents Vol. 96, 2012 (2012) (0)
- POSITIVE LYMPH NODE RATIO AND THE SURVIVAL AFTER PANCREATECTOMY FOR CANCER OF THE PANCREATIC HEAD (2008) (0)
- [5 -fluoropyrimidines for treatment of biliary tract cancers]. (2006) (0)
- Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). (2017) (0)
- Plasma biomarker for detecting early stage and risk disease of pancreatic cancer by Apolipoprotein-A2 isoforms (2016) (0)
- WS1. the expansion of surgical indication in gastric colorectal cancer drug therapy (2012) (0)
- O3-5-1Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors or hepatocellular carcinoma (2016) (0)
- Endoscopic ultrasound-guided choledochojejunostomy using a forward-viewing echoendoscopic saddle-cross technique (2022) (0)
- SY2-7NEW AGENTS UNDER DEVELOPMENT FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN JAPAN (2014) (0)
- Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma (2022) (0)
- Comparison of 6-mm and 10-mm-diameter, fully-covered, self-expandable metallic stents for distal malignant biliary obstruction (2022) (0)
- Supplemental Information Genomic Sequencing Identi fi es ELF 3 as a Driver of Ampullary Carcinoma (0)
- Extrapulmonary neuroendocrine tumors: An institutional experience of 337 patients at the National Cancer Center Hospital in Japan. (2011) (0)
- EP1147: PHASE II STUDY OF PREOPERATIVE S-1, IRINOTECAN PLUS OXIARIPLATINE COMBINATION THERAPY (S-IROX) FOR BORDERLINE RESECTABLE PANCREATIC CANCER (2022) (0)
- A Phase 3 Trial of Ganitumab with Gemcitabine as First-Line Treatment of Metastatic Pancreatic Cancer: A Safety Update from the Gamma Trial (2012) (0)
- A phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333 (2005) (0)
- Subject Index Vol. 64, 2003 (2003) (0)
- Diagnostic Ability of Endoscopic Ultrasound-Guided Tissue Acquisition Using 19-Gauge Fine-Needle Biopsy Needle for Abdominal Lesions (2023) (0)
- Analysis of prognostic factors in locally advanced and metastatic pancreatic cancer treated with gemcitabine or gemcitabine and S-1 chemotherapy using individual patient data from three randomized studies. (2014) (0)
- Simultaneous endoscopic ultrasound-guided hepaticogastrostomy and bridging stenting with partial stent-in-stent method (2020) (0)
- Efficacy, safety, and cancer-related symptoms in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies (2019) (0)
- The influence of renal function on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113. (2019) (0)
- Management of Local and Distant Recurrence after Pancreatic Cancer Resection (2015) (0)
- MO2-3 Nal-IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer – Additional safety report of randomized Japanese phase 2 trial (2022) (0)
- Protocol of a randomized phase II/III study of gemcitabine plus nab-paclitaxel combination therapy versus modified FOLFIRINOX versus S-IROX for metastatic or recurrent pancreatic cancer: JCOG1611 (GENERATE) (2022) (0)
- Pancreatic Cancer JS-5 Treatment ot Locally Unresectable Pancreatic Cancer with Chemoradiotherapy (2008) (0)
- : Study Group The Hepatobiliary and Pancreatic Oncology ( HBPO ) Group of the Japan Clinical Oncology Group ( JCOG ) : History and Future Direction (2012) (0)
- Influence of obstructive jaundice on chemotherapy in patients with unresectable biliary tract cancer. (2014) (0)
- Longitudinal comparisons of results in surgical resection and percutaneous ethanol injection therapy (PEI): Change in treatment strategy for small hepatocellular carcinoma (HCC) (2004) (0)
- Clinical features of young patients (below age 40) with pancreatic ductal adenocarcinoma. (2014) (0)
- P1-8-8FOLFIRINOX for locally advanced or metastatic pancreatic cancer: a single institution retrospective review (2015) (0)
- A multicenter phase II study of sorafenib in Japanese patients with hepatocellular carcinoma and Child Pugh A or B cirrhosis. (2014) (0)
- Subject Index Vol. 58, 2000 (2000) (0)
- Validation study of combination chemotherapy in vitro for biliary tract carcinoma. (2015) (0)
- Retrospective analysis of systemic chemotherapy for unresectable advanced biliary tract cancer (2005) (0)
- Correction: The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry (2022) (0)
- Current therapeutic strategy of unresectable pNET in Japan (2013) (0)
- Gemcitabine+nab-paclitaxel as first-line regimen for patients with advanced pancreatic cancer in real-world clinical practice: A retrospective study (2016) (0)
- O2-9-2Modified FOLFIRINOX in pancreatic cancer patients with double variant type of UGT1A1 polymorphism (2015) (0)
- Endoscopic ultrasonography-guided hepaticogastrostomy with parenchymal metal stent placement (2022) (0)
- Analysis of early tumor shrinkage and depth of response in patients with advanced biliary tract cancer treated with gemcitabine plus cisplatin or gemcitabine plus S-1: An exploratory analysis of JCOG1113. (2021) (0)
- Bile duct radiofrequency ablation for a residual adenoma after endoscopic papillectomy (2022) (0)
- EBM-based Clinical Guidelines for Pancreatic Cancer (2013): perspectives on chemotherapy (2014) (0)
- [Chemotherapy for gallbladder cancer]. (2013) (0)
- [Hepatocellular carcinoma]. (2010) (0)
- Trends of epidemiology of pancreatic and gastrointestinal neuroendocrine tumors in Japan (2014) (0)
- 43 POSTER Assessment of predictive biological markers with an oral angiogenic receptor tyrosine kinase (RTK) inhibitor, TSU-68, in the Phase I/II study for advanced hepatocellular carcinoma (HCC) (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Takuji Okusaka?
Takuji Okusaka is affiliated with the following schools:
